Drug Type Bispecific antibody, Probody |
Synonyms Costim bispecific Janux Therapeutics, Costimbispecific, costimulatory bispecific TRACIr + [2] |
Target |
Action agonists |
Mechanism CD28 agonists(T-cell-specific surface glycoprotein CD28 agonists), PDL1 agonists(Programmed death-ligand 1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | United States | - |